Ibrutinib

Ibrutinib is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor used in the treatment of B-cell malignancies including mantle cell lymphoma, CLL, and Waldenström's macroglobulinemia. Mediocon Inc supplies high-purity Ibrutinib API meeting IP/BP/EP/USP standards.

Key Features

• First-in-class BTK inhibitor
• IP/BP/EP/USP compliant quality
• High chemical purity >99%
• Suitable for oncology formulations

Applications

• Chronic lymphocytic leukemia (CLL)
• Mantle cell lymphoma
• Waldenström's macroglobulinemia
• Small lymphocytic lymphoma

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings